QBE: Shrinking upside
QBE has announced it will probably lose another US$900m in premiums. Nathan Bell explains why we’re finally losing patience.
Suncorp CPS3: If you're Suncorp, why not?
Suncorp CPS3 is a classic case of doing a deal because the going’s good. Good for Suncorp that is. Richard Livingston explains.
Blue chip battle: Cochlear v. ResMed
In a fierce head to head contest (well, fiercish), Cochlear wins on quality but ResMed trumps it for value.
All eyes on Vision
Australia’s largest network of eye clinics has come a long way from its darker days. Let’s put some numbers on its future.
Soul Patts and Brickworks: Interims 2014
The Soul Patts/Brickworks saga takes the back seat as both businesses release interim results.
Bargain hunting at The Reject Shop
With the price down 40% in two months, Graham Witcomb goes looking for a bargain and comes up trumps.
Fleetwood: A buy after the bust?
Fleetwood's dramatic decline is either the inevitable end of a frothy boom or an opportunity for the patient. Gaurav Sodhi decides.
Turn off the TELYS4
With Seven Group's deteriorating finances and the seemingly distant prospect of redemption, we're tuning out of these income securities.
Abacus: Interim result 2014 and SPP
Abacus Property delivered a sound interim result, but the office market is starting to look shaky.
Metcash model is fundamentally flawed
This retailer's latest strategic review highlights its problems, but the suggested solutions are unlikely to fix them.
M2: Interim result 2014
The squabbling continues over the NBN, but M2 should be able to earn its crust whoever's allowed to build what.
SomnoMed: Interim result 2014
Unit sales and revenues are growing strongly at SomnoMed, although higher profits will have to wait as the company continues to invest.
Sirtex targets growing market
This developer of treatments for liver cancer has been an excellent performer, but what's it really worth?
Call 1300 880 160
Start a chat
Schedule a call
